CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02166255
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:53.352553+00:00
Published At: 2018-07-03T00:00:00+00:00
Record Updated At: 2018-07-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Melanoma", "Recurrent Pancreatic Cancer", "Recurrent Renal Cell Cancer", "Stage III Pancreatic Cancer", "Stage III Renal Cell Cancer", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Unspecified Adult Solid Tumor, Protocol Specific"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-07-03"
protocolSection.identificationModule.nctId: "NCT02166255"
protocolSection.identificationModule.officialTitle: "A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.